{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03177538: Phase 4 Interventional Completed Infertility, Female
(2017)
Source URL:
First approved in 2005
Source:
PLUSET by Minitube of America, Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
ANDA205563
(1989)
Source URL:
First approved in 1989
Source:
ANDA205563
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333B
(2021)
Source URL:
First approved in 1984
Source:
NADA128409
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NDA018613
(1982)
Source URL:
First approved in 1982
Source:
NDA018613
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Fiblaferon by Bioferon [W. Germany]
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2023)
Source:
BLA761204
(2023)
Source URL:
First approved in 2023
Source:
BLA761204
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA020898
(1998)
Source URL:
First approved in 1998
Source:
BLA020898
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
BLA021765
(2004)
Source URL:
First approved in 1997
Source:
BLA020378
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
First approved in 1987
Source:
PROLASTIN-C by GRIFOLS THERAPEUTICS LLC
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
BLA021149
(2000)
Source URL:
First approved in 1976
Source:
BLA017692
Source URL:
Class:
PROTEIN
